David Hallal
About David Hallal
David Hallal: Chief Executive Officer & Chairman
David Hallal is the Chief Executive Officer and Chairman of ElevateBio, a prominent player in the biotechnology industry. With extensive experience in pharmaceutical sales and leadership roles, Hallal's vision is to build a world-class center of excellence in genome engineering. He aims to redefine how biotech companies operate and innovate.
David Hallal's Background in Biotechnology
David Hallal co-founded ElevateBio in 2017 and has a significant background in building and leading successful biotechnology companies. Previously, he worked at Amgen during its early days, gaining valuable industry experience. He has focused on advancing cell and gene therapies through strategic partnerships, a critical aspect of his career.
ElevateBio: Partnerships and Collaborations
Under David Hallal's leadership, ElevateBio has formed several strategic partnerships to enhance its capabilities. Notable partnerships include a 10-year alliance with Massachusetts General Hospital, a five-year cell and gene therapy collaboration with Boston Children’s Hospital, and strategic collaborations with the California Institute for Regenerative Medicine, Moderna Therapeutics, and Novo Nordisk. These collaborations aim to advance cell and gene therapies and genome engineering.
David Hallal's Fundraising Efforts for ElevateBio
David Hallal has been instrumental in securing significant funding for ElevateBio. The company raised $150 million in Series A financing, $170 million in Series B financing, $525 million in Series C financing, and $401 million in Series D financing. These funds have been critical in propelling ElevateBio's growth and development in the biotech sector.
David Hallal's Contributions to Biotech Discussions
David Hallal has contributed to discussions on biotech history and industry trends. He recorded an episode for 'The Long Run' podcast, sharing insights from his extensive experience in the biotechnology field. His participation in such discussions underscores his thought leadership and deep understanding of the biotech landscape.